Pioneering transformative breakthroughs that redefine discovery.
MISSION
Pioneering functional immunomics to uncover key immune cell pathways that will shape the future of next-generation immunotherapies for cancer and autoimmune diseases.
ABOUT
We approach discovery challenges, such as identifying the unique pathways that regulate immune cytotoxicity in specific cancers, with our proprietary Intelligent Design™ technology, empowered by AI-driven bioinformatics and led by our mission focused team of scientists, engineers, and clinicians.
Approach
PRECISION. PERSONALIZATION. INNOVATION.
At Feromics, we combine our Intelligent Design™ technology with deep biological insights to develop highly effective immunotherapy treatments. Our approach begins with the creation of proprietary libraries of interacting disease and immune cells divided by phenotypic functionalities such as cancer cell killing. Through the integration of AI and deep learning, we uncover novel, therapeutically relevant function-specific pathways that drive our capabilities and solutions in multiple areas, including the design and optimization of CAR-T and CAR-Treg constructs to enhance efficacy and safety in immunotherapies. Selection of donors for allogeneic immunotherapies ensures donor cells provide high therapeutic efficacy and patient compatibility. Derisking preclinical and clinical development streamlines the transition from research to clinical application and tailoring treatments to individual patient based on their unique immune profiles for improved therapeutic outcomes.
Partnerships
BETTER TOGETHER
Learn how our Intelligent Design™ technology and mission-focused team can empower discovery through functional immunomics to uncover key immune cell pathways and help expand and strengthen immunotherapy pipelines.
Grants
SUPPORTING OUR RESEARCH
Awarded up to $4M 3-year contract from the Advanced Research Projects Agency for Health (ARPA-H) to develop a precision medicine technology to improve patient treatment selection in cancer immunotherapy.
Under Contract No. 75N91024C00036 the Advanced Research Projects Agency for Health (ARPA-H), part of the Department of Health and Human Services, supports cutting-edge transformative biomedical and health breakthroughs.
OUR STORY
The story of Feromics began at the research laboratory of Professor Tania Konry at Northeastern University, where a team of engineers, biologists, and computer scientists developed a novel biotechnology that drives single-cell assay models for cancer and autoimmune disease. This breakthrough effort began in 2013 and resulted in over 52 scientific papers and patents, and collaborations with leading pharmaceutical companies. In 2022, Dr. Shai Schubert joined Dr. Konry as CEO to co-found Feromics, bringing the strategy, vision and leadership that drives our mission to develop innovative treatments that drive impactful, life-changing outcomes.
OUR PEOPLE
-
Tania Konry Ph.D., Biotech Lead / Co-FounderDr. Tania Konry is dedicated to advancing innovative healthcare solutions to improve patient outcomes. She holds a Ph.D. in Biotechnology and received advanced training in bioengineering at the Center for Engineering in Medicine at Massachusetts General Hospital (MGH), Harvard Medical School (HMS). Dr. Konry is an Associate Professor in the Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, and serves as the Assistant Dean for Research at the School of Pharmacy and Pharmaceutical Sciences (SOPPS) at Northeastern University. Before establishing her groundbreaking research initiatives at Feromics, she led technology development in multiple biotechnology and biomedical device ventures.
-
Shai Schubert Ph.D., CEO / Co-FounderDr. Schubert's mission is to bring transformative treatments to underserved patients. Prior to co-founding Feromics, Shai co-founded and led technology development in several biotechnology and medical device companies. Shai holds a Ph.D. in biotechnology from the Technion (IIT) and completed his postdoctoral training at the Harvard-MIT Program in Health Sciences and Technology, Biomedical Engineering Center (HST).
-
Dr. Donald ShafferDr. Donald Shaffer is the Head of Immuno-Oncology Cell Therapy at Sanofi. Dr Shaffer has extensive experience in cell therapy and drug development across both academia and industry. For the past 12 years, he has worked in the biotechnology and pharmaceutical industry, leading teams in the development of immuno-oncology drugs and cell therapies—first at Jounce Therapeutics and now at Sanofi.
-
Irene M. Ghobrial, MDDr. Ghobrial is the Senior Vice President for Experimental Medicine, Director of the Center for Early Detection and Interception of Blood Cancers, Co-Leader of the Lymphoma/Myeloma Cancer Center Program, Lavine Family Chair for Preventative Cancer Therapies, Director of the Ghobrial Lab, and Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School. She has authored over 300 articles and book chapters and her career-long contributions to translational research have been recognized with the William Dameshek Prize from the American Society of Hematology, the National Cancer Institute Outstanding Investigator Award, and the Jan Gosta Waldenstrom Award from the International Workshop on Waldenstrom’s Macroglobulinemia.
-
Andreas Klein, MDDr. Andreas Klein, Associate Professor of Medicine at Tufts Medical School and Associate Chief of the Division of Hematology/Oncology at Tufts Medical Center, also serves as Director of the Hematologic Malignancies Program and Bone Marrow and Hematopoietic Cell Transplant Program. Dr. Klein earned his medical degree from Yale University School of Medicine and brings over two decades of clinical expertise in hematologic malignancies and immune effector cell therapies. As Director of the Transplant and Cellular Therapy Program, he contributed to advancements in stem cell transplantation, including umbilical cord blood and haploidentical transplantation, as well as commercial CAR-T therapies. Actively engaged in five Phase I/II CAR-T clinical trials targeting malignant and autoimmune conditions, Dr. Klein seamlessly integrates cutting-edge translational research into clinical applications, advancing patient care and the development of innovative therapies.
-
Dr. Vladimir SenyukovDr. Vladimir Senyukov is an expert in cell-based immunotherapy with extensive academic and industry experience spanning CAR-T and NK cell therapy research, development, and commercialization. His work has contributed to the successful regulatory approvals of CAR-T products, including tisagenlecleucel (Kymriah). With a Ph.D. in Immunology from the Research Institute for Fundamental and Clinical Immunology in Novosibirsk, Russia, and postdoctoral training at M.D. Anderson Cancer Center Dr. Senyukov has led teams in analytical strategy development for cell therapies at Novartis, Precision BioSciences, Legend Bio and currently at Imugene.